undamentalytics Newsletter
Sign in

Cocrystal Pharma, Inc. (COCP) stock

Add to watchlist

Add holding +

NASDAQ: COCP Nasdaq Biotechnology

Cocrystal Pharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling11 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds8 adding, 12 cuttingOf 4 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Operating margin expanding: TTM operating margin reached -476.0%, up 261.5pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 261.5 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 69.3% over the last 12 months.
  • Loss-making. Operating margin is -476.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -500.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 46.0% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 28.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 75% and a beta of 1.5 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.23 against an average estimate of -$0.17: missed by 39.4%
Revenue
$0m

Cocrystal Pharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+6.0%
  • 1 week+9.3%
  • 1 month-7.8%
  • This year+8.2%
  • 1 year-2.8%
  • 5 years-90.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-0.76

Growth

Share count change
+28.7%

Earnings

Last results
March 31, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Announcement
  4. Agreement
  5. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cocrystal Pharma, Inc. valuation models and calculator

No model value for Cocrystal Pharma, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.72 +7% $110m 0%
Next −$0.47 +35% — −100%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.8% on 90 days ago. In the last 30 days, 1 analyst raised Cocrystal Pharma, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Cocrystal Pharma, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.69 Current fiscal year, 60 days ago: −$0.69 Current fiscal year, 30 days ago: −$0.69 Current fiscal year, 7 days ago: −$0.69 Current fiscal year, Now: −$0.72 −$0.72 Next fiscal year, 90 days ago: −$0.64 Next fiscal year, 60 days ago: −$0.64 Next fiscal year, 30 days ago: −$0.58 Next fiscal year, 7 days ago: −$0.58 Next fiscal year, Now: −$0.47 −$0.47

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.69−$0.64
60 days ago −$0.69−$0.64
30 days ago −$0.69−$0.58
7 days ago −$0.69−$0.58
Now −$0.72−$0.47

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.17 −$0.23 −39.4%
Mar 2026 −$0.15 −$0.17 −13.3%
Dec 2025 −$0.17 −$0.17 +2.9%
Sept 2025 −$0.21 −$0.19 +11.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202611

Counts of recommendations published by analysts covering Cocrystal Pharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.1%
of tradable shares
Days to cover
3.97
at average volume
Short interest, 1 month
−44%
to October 15, 2026
Held by institutions
6%
of shares
Held by insiders
65.7%
of shares
Employees
10
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
COCP−52%−75%−12%+17%−52%+8%
Industry peers (median)−35%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
COCP33%25%58%42%25%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
COCP−72%−79%−54%−43%−63%−48%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from December 31, 2015 to July 31, 2026. Getting back needed a 38973% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.82 – $1.57
From 52-week high
−32.5%
vs 50-day average
−3.6%
vs 200-day average
−3.8%
Volatility (1 year)
75%
Beta vs S&P 500
1.52

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.5%
After a week
5 up, 7 down
typical move ±11.8%
After a month
5 up, 7 down
typical move ±16.0%
Results releasedNext dayS&P 500 next day5 days21 days
March 31, 2026 +2.0% +3.7% +44.0% +43.0%
November 14, 2025 −1.0% −0.9% −12.6% −4.9%
August 14, 2025 +1.2% −0.2% −10.1% −14.9%
May 15, 2025 −2.7% +1.1% 0.0% 0.0%
March 31, 2025 −4.1% +1.0% −14.9% +2.0%
November 13, 2024 +25.0% −0.6% +17.0% +8.5%
August 14, 2024 −10.0% +2.0% +0.5% −12.1%
May 13, 2024 +8.1% +0.5% +9.8% +61.8%
March 28, 2024 0.0% −0.2% +6.7% +2.7%
November 13, 2023 −1.1% +1.8% −13.7% −5.3%
August 16, 2023 −7.1% −1.5% −1.7% −32.9%
May 15, 2023 −3.8% −0.3% −10.6% −3.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Cocrystal Pharma, Inc.
$0 $2M $4M $6M $8M FY19 Q4 FY20 Q1 FY20 Q2 FY20 Q3 FY20 Q4 Revenue (TTM), FY19 Q4: $6.6M Revenue (TTM), FY20 Q1: $1.9M Revenue (TTM), FY20 Q2: $1.9M Revenue (TTM), FY20 Q3: $1.9M Revenue (TTM), FY20 Q4: $2M $2M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY19 Q4 $6.6M
FY20 Q1 $1.9M
FY20 Q2 $1.9M
FY20 Q3 $1.9M
FY20 Q4 $2M
Operating margin (TTM) Cocrystal Pharma, Inc.
-3000% -2000% -1000% 0% FY19 Q4 FY20 Q1 FY20 Q2 FY20 Q3 FY20 Q4 Operating margin (TTM), FY19 Q4: -737.4% Operating margin (TTM), FY20 Q1: -2734.7% Operating margin (TTM), FY20 Q2: -2888.6% Operating margin (TTM), FY20 Q3: -2940.5% Operating margin (TTM), FY20 Q4: -476.0% -476.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY19 Q4 -737.4%
FY20 Q1 -2734.7%
FY20 Q2 -2888.6%
FY20 Q3 -2940.5%
FY20 Q4 -476.0%
FCF margin (TTM) Cocrystal Pharma, Inc.
-600% -400% -200% 0% FY19 Q4 FY20 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FCF margin (TTM), FY19 Q4: -26.0% FCF margin (TTM), FY20 Q1: -307.2% FCF margin (TTM), FY20 Q2: -381.2% FCF margin (TTM), FY20 Q3: -467.9% FCF margin (TTM), FY20 Q4: -500.0% -500.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY19 Q4 -26.0%
FY20 Q1 -307.2%
FY20 Q2 -381.2%
FY20 Q3 -467.9%
FY20 Q4 -500.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2019 Dec 2019 2020 Dec 2020
Income
Revenue 13 7 2
Gross profit 3 — —
EBITDA −3 −48 −9
Operating income −4 −48 −10
Net income −5 −48 −10
Diluted EPS −$1.32 −$18.12 −$2.04
Growth (year on year)
Revenue — −48.4% −69.3%
Margins
Gross margin 21.1% — —
EBITDA margin −26.4% −736.3% −468.2%
Operating margin −30.6% −737.4% −476.0%
Net margin −42.9% −733.8% −479.0%
Free-cash-flow margin −7.8% −26.0% −500.0%
Cash flow
Cash from operations −0 −2 −10
Capital spending 1 0 0
Free cash flow −1 −2 −10
Stock-based pay — 0 1
Free cash flow after stock pay — −2 −11
Balance sheet
Cash 0 7 33
Total debt 5 0 0
Net debt (negative = net cash) 5 −7 −33
Diluted shares — — 5m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+28.7%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated COCP KRSA MCRB CLGN KRRO VTGN Median
Revenue, last 12 months $2m $2m $2m $2m $2m $3m $55m
Revenue growth, last 12 months −69.3% −12.6% 100.0% 360.4% −62.1% 287.3% 12.2%
Revenue growth, 3-year average — — −75.6% — −53.7% — 13.7%
Revenue growth, latest quarter 26.9% −100.0% 100.0% — −100.0% 504.9% 10.2%
Operating margin −476.0% −359.2% <−999% −484.3% <−999% <−999% −191.1%
Operating margin, 3-year average — <−999% <−999% — <−999% <−999% −363.5%
Net margin −479.0% −353.0% <−999% −484.6% <−999% <−999% −172.8%
Cash from operations / revenue −488.1% −234.3% <−999% −397.3% <−999% <−999% −168.8%
Free-cash-flow margin −500.0% <−999% <−999% −398.4% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average — — −900.2% — <−999% <−999% −310.0%
Stock pay / revenue 46.0% 16.9% 487.8% 42.1% 391.7% 162.7% 20.7%
Change in share count 28.7% 45.4% 11.0% 6.5% 28.2% 30.8% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$1.2M
Institutions reporting
26
Shares held vs prior quarter
▲ 43.3%
Positions opened / closed
5 / 6

Top buyers and sellers, Q2 2026: 8 institutions bought and 12 sold ; the biggest buyer was Two Sigma Investments, LP (+175K shares) and the biggest seller T3 Companies, LLC (−52K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $376,139 358K 32.2% ▲ 49.3%
Renaissance Technologies LLC $188,609 180K 16.2% ▲ 44.9%
Two Sigma Investments, LP $184,148 175K 15.8% New
Geode Capital Management, LLC $80,034 76K 6.9% ▼ 15.5%
Blackrock, Inc. $77,433 74K 6.6% 0.0%
Citadel Advisors LLC $47,374 45K 4.1% New
Neuberger Berman Group LLC $33,480 32K 2.9% 0.0%
Xtx Topco Ltd $30,809 29K 2.6% ▼ 18.6%
Jane Street Group, LLC $27,049 26K 2.3% ▲ 102.7%
Vanguard Fiduciary Trust Co $25,217 24K 2.2% 0.0%
State Street Corp $21,570 21K 1.8% 0.0%
HRT Financial LP $21,000 20K 1.8% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cocrystal Pharma, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $300,525 11 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $300,525 net buying
Insider Date Trade Shares Price Value
Frost Phillip Md Et Al Director August 5, 2026 Buy 10,000 $0.98 $9,800
Frost Phillip Md Et Al Director August 3, 2026 Buy 75,000 $0.94 $70,500
Frost Phillip Md Et Al Director February 24, 2026 Buy 20,000 $1.00 $20,000
Frost Phillip Md Et Al Director February 6, 2026 Buy 50,000 $0.95 $47,500
Frost Phillip Md Et Al Director December 31, 2025 Buy 50,000 $0.95 $47,500
Frost Phillip Md Et Al Director December 30, 2025 Buy 20,000 $0.97 $19,400
Frost Phillip Md Et Al Director December 26, 2025 Buy 40,000 $0.97 $38,800
Frost Phillip Md Et Al Director December 24, 2025 Buy 25,000 $0.97 $24,250
Frost Phillip Md Et Al Director November 26, 2025 Buy 1,500 $1.00 $1,500
Frost Phillip Md Et Al Director November 26, 2025 Buy 2,500 $0.99 $2,475
Frost Phillip Md Et Al Director November 25, 2025 Buy 20,000 $0.94 $18,800

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around July 1, 2026 estimated from the company's past filing pattern, not announced

  • March 31, 2026
  • November 14, 2025
  • August 14, 2025
  • May 15, 2025
  • March 31, 2025
  • November 13, 2024

Recent SEC filings

Data status

When each part of this page on Cocrystal Pharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cocrystal Pharma, Inc. in brief

What does Cocrystal Pharma, Inc. do?
Cocrystal Pharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Cocrystal Pharma, Inc.'s stock ticker?
Cocrystal Pharma, Inc. trades under the ticker COCP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Cocrystal Pharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Renaissance Technologies LLC and Two Sigma Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cocrystal Pharma, Inc.'s market cap?
On December 31, 2020, Cocrystal Pharma, Inc.'s market capitalisation was about $75.1M and net debt of -$33M. Market figures come from third-party market data and may be delayed.
Who are Cocrystal Pharma, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Cocrystal Pharma, Inc. are Korsana Biosciences, Inc., Seres Therapeutics, Inc., Collplant Biotechnologies Ltd, Korro Bio, Inc. and Vistagen Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Cocrystal Pharma, Inc.'s.
Are insiders buying or selling Cocrystal Pharma, Inc. stock?
Over the last 12 months, Cocrystal Pharma, Inc.'s directors and officers reported 11 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.